How to appeal an Aetna copd severe + alpha-1 antitrypsin deficiency denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for copd severe + alpha-1 antitrypsin deficiency

Cited policy: Aetna CPB on Ohtuvayre (Ensifentrine) for COPD Maintenance

COPD with documented obstruction (FEV1/FVC <0.70 + post-BD FEV1 <80%). Step therapy through LAMA/LABA and triple inhaled therapy.

How Aetna denies copd severe + alpha-1 antitrypsin deficiency — and how to counter it

Where Aetna pushes back: 1) Try Trelegy/Breztri first; 2) Insufficient COPD severity; 3) Experimental.

Counter-arguments that hold up: FDA approved Jun 26, 2024 — first novel COPD inhaled mechanism in 20+ years. ENHANCE-1/2 enrolled patients on maximal triple — show maximal triple already in place x ≥3 months. Trough FEV1 +87 to +94 mL vs placebo. PDE3/PDE4 inhibitor distinct from inhaled LAMA/LABA/ICS.

What Aetna typically denies for copd severe + alpha-1 antitrypsin deficiency

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For copd severe + alpha-1 antitrypsin deficiency, expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the copd severe + alpha-1 antitrypsin deficiency treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Dupixent (eos COPD)
• Ohtuvayre
• Trelegy
• Breztri
• Open triple
• Roflumilast

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.